Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

Maire, Virginie, Némati, Fariba, Richardson, Marion, Vincent-Salomon, Anne, Tesson, Bruno, Rigaill, Guillem, Gravier, Eléonore, Marty-Prouvost, Bérengère, De Koning, Leanne, Lang, Guillaume, Gentien, David, Dumont, Aurélie, Barillot, Emmanuel, Marangoni, Elisabetta, Decaudin, Didier, Roman-Roman, Sergio, Pierré, Alain, Cruzalegui, Francisco, Depil, Stéphane, Tucker, Gordon C., Dubois, Thierry · 2013 · Cancer Research

Abstract

Breast cancers are composed of molecularly distinct subtypes with different clinical outcomes and responses to therapy. To discover potential therapeutic targets for the poor prognosis-associated triple-negative breast cancer (TNBC), gene expression profiling was carried out on a cohort of 130 breast cancer samples. Polo-like kinase 1 (PLK1) was found to be significantly overexpressed in TNBC compared with the other breast cancer subtypes. High PLK1 expression was confirmed by reverse phase protein and tissue microarrays. In triple-negative cell lines, RNAi-mediated PLK1 depletion or inhibition of PLK1 activity with a small molecule (BI-2536) induced an increase in phosphorylated H2AX, G2–M arrest, and apoptosis. A soft-agar colony assay showed that PLK1 silencing impaired clonogenic potential of TNBC cell lines. When cells were grown in extracellular matrix gels (Matrigel), and exposed to BI-2536, apoptosis was observed specifically in TNBC cancerous cells, and not in a normal cell line. When administrated as a single agent, the PLK1 inhibitor significantly impaired tumor growth in vivo in two xenografts models established from biopsies of patients with TNBC. Most importantly, the administration of BI-2536, in combination with doxorubicin + cyclophosphamide chemotherapy, led to a faster complete response compared with the chemotherapy treatment alone and prevented relapse, which is the major risk associated with TNBC. Altogether, our observations suggest PLK1 inhibition as an attractive therapeutic approach, in association with conventional chemotherapy, for the management of patients with TNBC. Cancer Res; 73(2); 813–23. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-2633

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 194

Metadata

Authors
Maire, V., Némati, F., Richardson, M., Vincent-Salomon, A., Tesson, B., Rigaill, G., Gravier, E., Marty-Prouvost, B., De Koning, L., Lang, G., Gentien, D., Dumont, A., Barillot, E., Marangoni, E., Decaudin, D., Roman-Roman, S., Pierré, A., Cruzalegui, F., Depil, S., Tucker, G. C., & Dubois, T.
Venue
Cancer Research
Published
2013-01-15
Volume
73
Issue
2
Pages
813-823
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2082793779
Cited by
194
References
4
FWCI
3.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-2633
The paper
Maire, V., Némati, F., Richardson, M., Vincent-Salomon, A., Tesson, B., Rigaill, G., Gravier, E., Marty-Prouvost, B., De Koning, L., Lang, G., Gentien, D., Dumont, A., Barillot, E., Marangoni, E., Decaudin, D., Roman-Roman, S., Pierré, A., Cruzalegui, F., Depil, S., . . . Dubois, T. (2013). Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-2633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.